Recent Developments in Atopic Dermatitis

Pediatrics. 2018 Oct;142(4):e20181102. doi: 10.1542/peds.2018-1102.

Abstract

Atopic dermatitis (AD) is a bothersome and common skin disease affecting ∼10.7% of children in the United States. This skin condition significantly decreases quality of life in not only patients, but in their families as well. Pediatricians are often the first physicians to diagnose and manage these patients and thus are relied on by families to answer questions about this disease. AD is complex, multifactorial, and has historically had limited therapeutic options, but the landscape of this disease is now rapidly changing. Pathways contributing to the pathogenesis of this disease are continually being discovered, and new therapies for AD are being developed at an unprecedented rate. With this article, we will review the current guidelines regarding the management of AD, outline updates in the current understanding of its pathophysiology, and highlight novel developments available for the treatment of this burdensome disease.

Publication types

  • Review

MeSH terms

  • Administration, Topical
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Child
  • Clinical Trials as Topic / methods
  • Dermatitis, Atopic / epidemiology*
  • Dermatitis, Atopic / psychology
  • Dermatitis, Atopic / therapy*
  • Humans
  • Quality of Life* / psychology
  • Skin Care / methods
  • Skin Care / psychology
  • Skin Care / trends*

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • dupilumab